Vestal Point Capital
Latest statistics and disclosures from Vestal Point Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are RVMD, BMRN, ABVX, NBIX, ARWR, and represent 25.37% of Vestal Point Capital's stock portfolio.
- Added to shares of these 10 stocks: RVMD (+$202M), NBIX (+$165M), RGEN (+$99M), ARWR (+$86M), DYN (+$70M), SNY (+$68M), IMCR (+$66M), BSX (+$50M), COGT (+$47M), GLUE (+$47M).
- Started 37 new stock positions in ZURA, PODD, INSP, VCYT, NBIX, UTHR, WGS, NKTR, SNY, URGN.
- Reduced shares in these 10 stocks: QQQ (-$215M), ACLX (-$191M), TERN (-$185M), TYRA (-$91M), DXCM (-$85M), , ABT (-$75M), GMED (-$57M), , DAWN (-$49M).
- Sold out of its positions in ABT, ALEC, ACLX, AXSM, BDTX, DBVT, DAWN, DXCM, FATE, GILD. QQQ, LNTH, LENZ, MRK, MNMD, MIRM, PEN, RZLT, GPCR, STRO, UPB, ZYME, JAZZ.
- Vestal Point Capital was a net buyer of stock by $544M.
- Vestal Point Capital has $3.6B in assets under management (AUM), dropping by 21.61%.
- Central Index Key (CIK): 0001974915
Tip: Access up to 7 years of quarterly data
Positions held by Vestal Point Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Vestal Point Capital
Vestal Point Capital holds 90 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Revolution Medicines (RVMD) | 6.5 | $231M | +705% | 2.4M | 97.25 |
|
| BioMarin Pharmaceutical (BMRN) | 5.6 | $202M | +19% | 3.6M | 56.49 |
|
| Abivax SA Sponsored Ads (ABVX) | 4.7 | $167M | -21% | 1.5M | 111.35 |
|
| Neurocrine Biosciences (NBIX) | 4.6 | $165M | NEW | 1.3M | 131.74 |
|
| Arrowhead Pharmaceuticals (ARWR) | 4.0 | $143M | +152% | 2.3M | 62.70 |
|
| Enliven Therapeutics (ELVN) | 3.6 | $127M | -15% | 3.3M | 39.20 |
|
| Repligen Corporation (RGEN) | 3.0 | $109M | +1014% | 925k | 117.82 |
|
| Bicara Therapeutics (BCAX) | 3.0 | $108M | +51% | 5.4M | 19.89 |
|
| Nurix Therapeutics (NRIX) | 2.8 | $101M | +38% | 6.5M | 15.50 |
|
| Apogee Therapeutics (APGE) | 2.6 | $93M | +100% | 1.1M | 84.17 |
|
| Ascendis Pharma A/S Sponsored Adr (ASND) | 2.4 | $86M | +114% | 375k | 228.73 |
|
| Immunocore Holdings Ads (IMCR) | 2.3 | $83M | +372% | 2.8M | 30.15 |
|
| Taysha Gene Therapies Com Shs (TSHA) | 2.2 | $81M | +30% | 18M | 4.47 |
|
| Dyne Therapeutics (DYN) | 2.0 | $73M | +3233% | 4.0M | 18.13 |
|
| Sanofi SA Sponsored Adr (SNY) | 1.9 | $68M | NEW | 1.4M | 48.18 |
|
| BioCryst Pharmaceuticals (BCRX) | 1.9 | $67M | +212% | 7.0M | 9.52 |
|
| Scholar Rock Hldg Corp (SRRK) | 1.8 | $65M | +89% | 1.3M | 49.16 |
|
| Immatics NV SHS (IMTX) | 1.7 | $61M | 6.2M | 9.84 |
|
|
| Bristol Myers Squibb (BMY) | 1.7 | $61M | +300% | 1.0M | 60.65 |
|
| Alcon Ord Shs (ALC) | 1.7 | $60M | -27% | 800k | 75.35 |
|
| Monte Rosa Therapeutics (GLUE) | 1.7 | $59M | +364% | 3.6M | 16.45 |
|
| Vera Therapeutics Cl A (VERA) | 1.5 | $55M | +148% | 1.4M | 40.23 |
|
| Terns Pharmaceuticals (TERN) | 1.5 | $53M | -77% | 1.0M | 52.72 |
|
| Globus Medical Cl A (GMED) | 1.5 | $53M | -52% | 611k | 86.16 |
|
| Boston Scientific Corporation (BSX) | 1.4 | $50M | NEW | 800k | 62.75 |
|
| Nuvalent Inc-a (NUVL) | 1.4 | $49M | +947% | 482k | 102.45 |
|
| Cogent Biosciences (COGT) | 1.3 | $47M | NEW | 1.2M | 38.49 |
|
| Alto Neuroscience Com Shs (ANRO) | 1.3 | $46M | -16% | 2.1M | 22.48 |
|
| Rapport Therapeutics (RAPP) | 1.3 | $45M | +29% | 1.4M | 31.29 |
|
| Disc Medicine (IRON) | 1.3 | $45M | -4% | 700k | 63.94 |
|
| United Therapeutics Corporation (UTHR) | 1.2 | $45M | NEW | 75k | 592.98 |
|
| Celldex Therapeutics Com New (CLDX) | 1.1 | $39M | +5% | 1.2M | 31.72 |
|
| Kalvista Pharmaceuticals (KALV) | 1.0 | $37M | -2% | 1.9M | 20.13 |
|
| Xenon Pharmaceuticals (XENE) | 1.0 | $37M | +6% | 640k | 58.15 |
|
| Solid Biosciences Com New (SLDB) | 1.0 | $36M | -14% | 5.0M | 7.20 |
|
| Bright Minds Biosciences Com New (DRUG) | 1.0 | $36M | NEW | 492k | 72.97 |
|
| Protagonist Therapeutics (PTGX) | 1.0 | $34M | NEW | 326k | 105.40 |
|
| Denali Therapeutics (DNLI) | 1.0 | $34M | +281% | 1.8M | 19.20 |
|
| Regeneron Pharmaceuticals (REGN) | 0.9 | $31M | NEW | 40k | 772.64 |
|
| Waters Corporation (WAT) | 0.8 | $30M | NEW | 100k | 297.80 |
|
| Viking Therapeutics (VKTX) | 0.8 | $30M | NEW | 914k | 32.54 |
|
| Inspire Med Sys (INSP) | 0.8 | $28M | NEW | 539k | 51.58 |
|
| Crescent Biopharma (CBIO) | 0.8 | $28M | 1.5M | 18.37 |
|
|
| Trevi Therapeutics (TRVI) | 0.7 | $26M | NEW | 2.2M | 11.93 |
|
| Lexeo Therapeutics (LXEO) | 0.7 | $26M | 4.5M | 5.74 |
|
|
| Soleno Therapeutics (SLNO) | 0.7 | $24M | NEW | 730k | 33.48 |
|
| Beta Bionics (BBNX) | 0.6 | $22M | +268% | 2.2M | 10.02 |
|
| Nektar Therapeutics Com New (NKTR) | 0.6 | $21M | NEW | 285k | 71.95 |
|
| Cytokinetics Com New (CYTK) | 0.6 | $20M | NEW | 300k | 65.91 |
|
| AstraZeneca Ord (AZN) | 0.6 | $20M | NEW | 100k | 197.22 |
|
| West Pharmaceutical Services (WST) | 0.5 | $19M | NEW | 75k | 250.64 |
|
| GE HealthCare Technologies Common Stock (GEHC) | 0.5 | $18M | NEW | 250k | 71.18 |
|
| SpyGlass Pharma Com Shs | 0.5 | $17M | NEW | 667k | 25.91 |
|
| Zimmer Holdings (ZBH) | 0.5 | $17M | +26% | 190k | 90.42 |
|
| Madrigal Pharmaceuticals (MDGL) | 0.5 | $17M | NEW | 32k | 523.47 |
|
| GeneDx Holdings Corp Com Cl A (WGS) | 0.4 | $16M | NEW | 250k | 64.22 |
|
| Damora Therapeutics Com New (DMRA) | 0.4 | $16M | NEW | 600k | 25.90 |
|
| Agios Pharmaceuticals (AGIO) | 0.4 | $15M | +38% | 450k | 33.83 |
|
| Engene Holdings (ENGN) | 0.4 | $15M | +105% | 2.2M | 6.81 |
|
| Savara (SVRA) | 0.4 | $14M | +61% | 2.6M | 5.46 |
|
| Tarsus Pharmaceuticals (TARS) | 0.4 | $14M | NEW | 200k | 70.15 |
|
| Voyager Therapeutics (VYGR) | 0.3 | $12M | +103% | 3.0M | 3.86 |
|
| Insulet Corporation (PODD) | 0.3 | $11M | NEW | 51k | 209.84 |
|
| Tectonic Therapeutic (TECX) | 0.3 | $10M | 328k | 30.91 |
|
|
| Surrozen Com New (SRZN) | 0.3 | $9.9M | NEW | 339k | 29.13 |
|
| Arvinas Ord (ARVN) | 0.3 | $9.6M | NEW | 906k | 10.60 |
|
| Maplight Therapeutics (MPLT) | 0.2 | $8.5M | +9% | 420k | 20.33 |
|
| Fulcrum Therapeutics (FULC) | 0.2 | $8.4M | +15% | 1.1M | 7.67 |
|
| OnKure Therapeutics Com Cl A (OKUR) | 0.2 | $7.6M | +189% | 1.8M | 4.14 |
|
| Myriad Genetics (MYGN) | 0.2 | $7.4M | +34% | 1.6M | 4.50 |
|
| Olema Pharmaceuticals (OLMA) | 0.2 | $6.4M | -74% | 429k | 14.91 |
|
| Anteris Technologies Global (AVR) | 0.2 | $6.4M | NEW | 1.1M | 5.55 |
|
| uniQure NV SHS (QURE) | 0.2 | $5.9M | NEW | 359k | 16.35 |
|
| Candel Therapeutics (CADL) | 0.2 | $5.5M | NEW | 1.1M | 4.90 |
|
| Palisade Bio (PALI) | 0.1 | $4.4M | NEW | 2.5M | 1.75 |
|
| Veracyte (VCYT) | 0.1 | $4.2M | NEW | 131k | 32.21 |
|
| Zenas Biopharma (ZBIO) | 0.1 | $3.9M | NEW | 200k | 19.55 |
|
| Geron Corporation (GERN) | 0.1 | $3.8M | -77% | 2.5M | 1.49 |
|
| Monopar Therapeutics Com New (MNPR) | 0.1 | $3.6M | NEW | 65k | 54.79 |
|
| Zura Bio Class A Ord Shs (ZURA) | 0.1 | $3.0M | NEW | 511k | 5.95 |
|
| Novocure Ord Shs (NVCR) | 0.1 | $2.7M | -52% | 250k | 10.90 |
|
| Nyxoah SA SHS (NYXH) | 0.1 | $2.5M | -21% | 869k | 2.92 |
|
| Urogen Pharma (URGN) | 0.1 | $2.5M | NEW | 139k | 17.98 |
|
| Passage Bio Com New (PASG) | 0.1 | $2.4M | 305k | 7.85 |
|
|
| Tyra Biosciences (TYRA) | 0.1 | $2.1M | -97% | 54k | 38.30 |
|
| Regenxbio Inc equity us cm (RGNX) | 0.0 | $909k | +219% | 109k | 8.38 |
|
| Tenax Therapeutics Com New (TENX) | 0.0 | $855k | 53k | 15.99 |
|
|
| Macrogenics (MGNX) | 0.0 | $809k | 280k | 2.89 |
|
|
| Absci Corp (ABSI) | 0.0 | $697k | NEW | 232k | 3.00 |
|
| Aprea Therapeutics Com New (APRE) | 0.0 | $267k | NEW | 350k | 0.76 |
|
Past Filings by Vestal Point Capital
SEC 13F filings are viewable for Vestal Point Capital going back to 2024
- Vestal Point Capital 2026 Q1 filed May 15, 2026
- Vestal Point Capital 2025 Q4 filed Feb. 17, 2026
- Vestal Point Capital 2025 Q3 filed Nov. 14, 2025
- Vestal Point Capital 2025 Q2 filed Aug. 14, 2025
- Vestal Point Capital 2025 Q1 filed May 15, 2025
- Vestal Point Capital 2024 Q4 filed Feb. 14, 2025
- Vestal Point Capital 2024 Q3 filed Nov. 14, 2024
- Vestal Point Capital 2024 Q2 filed Aug. 14, 2024